No Clinically Significant Drug-Drug Interactions Between Eliquis, Toprol, and Nurtec
These three medications can be safely used together without dose adjustments, as there are no clinically significant pharmacokinetic or pharmacodynamic interactions between apixaban (Eliquis), metoprolol (Toprol), and rimegepant (Nurtec).
Interaction Analysis by Drug Pair
Eliquis (Apixaban) and Toprol (Metoprolol)
Metoprolol is a beta-blocker that does not interact with apixaban's metabolic pathways. Apixaban is metabolized primarily by CYP3A4 and is a P-glycoprotein (P-gp) substrate 1, 2. Metoprolol is metabolized predominantly by CYP2D6 and does not significantly inhibit or induce CYP3A4 or P-gp 3. No interaction exists between these medications.
Eliquis (Apixaban) and Nurtec (Rimegepant)
Rimegepant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9, and is a substrate for P-gp 4. Apixaban is also a CYP3A4 and P-gp substrate but is not an inhibitor or inducer of these pathways at therapeutic concentrations 1, 5. The FDA label for rimegepant explicitly states it is not an inhibitor of P-gp at clinically relevant concentrations 4. These drugs do not affect each other's metabolism.
Toprol (Metoprolol) and Nurtec (Rimegepant)
Metoprolol is metabolized by CYP2D6, while rimegepant is metabolized by CYP3A4 and CYP2C9 4, 3. These are distinct metabolic pathways with no overlap. Neither drug inhibits or induces the other's metabolic enzymes. The FDA label for rimegepant confirms no significant pharmacokinetic interactions when co-administered with metoprolol 4. No interaction exists.
Important Clinical Considerations
Bleeding Risk Management
While there are no drug-drug interactions, monitor for bleeding when using apixaban, as this is the primary safety concern with any anticoagulant 1, 2. The bleeding risk is not increased by the addition of metoprolol or rimegepant specifically, but baseline bleeding risk assessment remains essential.
Renal Function Monitoring
All three medications require consideration of renal function:
- Apixaban: Dose reduction to 2.5 mg twice daily if patient meets ≥2 criteria: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 6, 2
- Metoprolol: No specific renal adjustments typically required
- Rimegepant: No renal dose adjustments in FDA labeling 4
Avoid Confusion with True Interacting Drugs
Do not confuse metoprolol with drugs that actually interact with apixaban, such as:
- Strong dual CYP3A4 and P-gp inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) - these increase apixaban levels significantly 1, 7, 5
- Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) - these decrease apixaban levels 1, 5
For rimegepant, avoid strong CYP3A4 inhibitors and inducers, and potent P-gp inhibitors (including amiodarone, cyclosporine, quinidine, ranolazine) 4. Metoprolol is not among these interacting drugs.
Cardiovascular Monitoring
Metoprolol's beta-blocking effects (bradycardia, hypotension) are independent of the other two medications. Standard monitoring for heart rate and blood pressure applies, but this is not an interaction-related concern.